

Amelia McCartney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7377484/publications.pdf>

Version: 2024-02-01

49
papers

858
citations

623188

14
h-index

500791

28
g-index

53
all docs

53
docs citations

53
times ranked

1377
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: A multicenter study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 570-577.	0.7	24
2	Lower COVID-19 vaccination rates amongst Australians with gastrointestinal (GI) compared to other cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 648-648.	0.8	0
3	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. <i>European Journal of Cancer</i> , 2022, 164, 39-51.	1.3	8
4	Abstract OT1-02-02: A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens. <i>Cancer Research</i> , 2022, 82, OT1-02-02-OT1-02-02.	0.4	0
5	250TiP HER2-positive and HER2-low breast cancer patients in the ACE-Pan tumor-01 study: Phase I study evaluating ARX788 as monotherapy in advanced solid tumors with HER2 expression or mutation. <i>Annals of Oncology</i> , 2022, 33, S223.	0.6	2
6	Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from Australia. <i>Vaccines</i> , 2022, 10, 851.	2.1	15
7	CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 93, 102136.	3.4	25
8	Abstract PS5-05: Serum thymidine kinase activity in patients with luminal metastatic breast cancer treated with palbociclib and fulvestrant within the PYTHIA trial. , 2021, , .		4
9	Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TReND trial. <i>Breast Cancer Research</i> , 2021, 23, 38.	2.2	14
10	Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4687.	1.8	23
11	Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpressing solid tumors: Results from two phase 1 clinical trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1038-1038.	0.8	16
12	A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting. <i>Cancers</i> , 2021, 13, 2762.	1.7	14
13	Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). <i>Lancet Oncology</i> , The, 2021, 22, e327-e340.	5.1	121
14	A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e332-e339.	1.1	3
15	Expanding the Scope of Geriatric Assessment for the Management of Cancer in Older Adults. <i>JAMA Oncology</i> , 2020, 6, 204.	3.4	2
16	Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3574.	1.7	42
17	EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 83.	2.2	6
18	The Conundrum of the Association of Chemotherapy With Survival Outcomes Among Elderly Patients With Curable Luminal Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1535.	3.4	10

#	ARTICLE	IF	CITATIONS
19	Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors. <i>British Journal of Cancer</i> , 2020, 123, 176-177.	2.9	4
20	Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TReEnd Trial. <i>Clinical Cancer Research</i> , 2020, 26, 2131-2139.	3.2	40
21	Neoadjuvant nab-paclitaxel in breast cancer: who stands to benefit?. <i>Chinese Clinical Oncology</i> , 2020, 9, 42-42.	0.4	0
22	Thymidine kinase-1 as a biomarker in breast cancer: estimating prognosis and early recognition of treatment resistance. <i>Biomarkers in Medicine</i> , 2020, 14, 495-498.	0.6	3
23	Abstract P5-06-11: Serum thymidine kinase-1 activity (TKa) as a prognostic marker in premenopausal women with hormone receptor positive (HR+) operable breast cancer (BC). , 2020, , .		0
24	Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. <i>Frontiers in Oncology</i> , 2019, 9, 666.	1.3	113
25	Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution. <i>Breast Journal</i> , 2019, 25, 1225-1229.	0.4	0
26	Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification. <i>Npj Breast Cancer</i> , 2019, 5, 26.	2.3	12
27	Estimating the magnitude of clinical benefit of chemotherapy in patients with early ER-positive, HER2-negative breast cancer. <i>Breast</i> , 2019, 44, S11.	0.9	1
28	The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. <i>Cancer Treatment Reviews</i> , 2019, 74, 29-34.	3.4	23
29	Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, 392-398.	1.1	12
30	Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TReEnd trial. <i>Breast Cancer Research</i> , 2019, 21, 71.	2.2	19
31	Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFFECT). <i>European Journal of Cancer</i> , 2019, 114, 55-66.	1.3	30
32	LEPTOMENINGEAL DISEASE: AN UPDATE. <i>Breast</i> , 2019, 48, S28-S29.	0.9	0
33	The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy. <i>Cancers</i> , 2019, 11, 1894.	1.7	53
34	An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989160.	1.4	3
35	Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancer. <i>Breast</i> , 2019, 48, S81-S84.	0.9	1
36	Abstract 4416: Plasma thymidine kinase activity in patients with luminal metastatic breast cancer treated with Palbociclib within the phase II TReEnd trial. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
37	Abstract 4416: Plasma thymidine kinase activity in patients with luminal metastatic breast cancer treated with Palbociclib within the phase II TREnd trial. , 2019, , .		0
38	Metabolomics in breast cancer: A decade in review. <i>Cancer Treatment Reviews</i> , 2018, 67, 88-96.	3.4	87
39	A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 329-341.	1.1	17
40	Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591881559.	1.4	5
41	Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature. <i>Anticancer Research</i> , 2018, 38, 4839-4845.	0.5	5
42	The role of abemaciclib in treatment of advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877692.	1.4	14
43	Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. <i>Annals of Oncology</i> , 2018, 29, 1748-1754.	0.6	76
44	Role of serum thymidine kinase-1 (TK1) activity in patients (pts) with hormone receptor positive (HR+) advanced breast cancer (ABC) treated with endocrine therapy (ET) in the EFECT trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12031-12031.	0.8	1
45	A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).. <i>Journal of Clinical Oncology</i> , 2018, 36, 570-570.	0.8	0
46	Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?. <i>Oncotarget</i> , 2018, 9, 34031-34032.	0.8	0
47	Systemic Treatment of Metastatic Breast Cancer (MBC) in Older Adults. <i>Breast</i> , 2017, 36, S24.	0.9	0
48	De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer. <i>Breast</i> , 2017, 34, S13-S18.	0.9	6
49	Gene signatures as potential predictive markers of response to neoadjuvant chemotherapy in ER+/HER2+ breast cancer patients. <i>Annals of Oncology</i> , 2017, 28, v25-v26.	0.6	0